Castleman Disease

Read full text Summarise with VIRAT
Authors: Prakash Sivaramakrishnan
Cited by: 0
References: 123

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Castleman disease (CD) is a rare, nonclonal lymphoproliferative disorder with varied clinical and pathological manifestations and often mimics malignancies or infections like tuberculosis. It is broadly classified into unicentric (UCD) and multicentric (MCD) forms, with MCD further subdivided into HHV-8–associated, idiopathic (iMCD), and TAFRO syndrome. The primary pathogenetic mechanism involves cytokine dysregulation (IL-6, VEGF), but can also include viral triggers (HHV-8) and genetic mutations. Diagnosis relies on histopathology (hyaline vascular or plasma cell variants) and exclusion of mimics such as lymphoma, TB. Imaging (CT/MRI/PET) aids in localization, guides biopsy, and serves as a prognostic marker in CD. IL-6 blockade (siltuximab) is first line for iMCD. UCD has excellent prognosis with surgery, whereas MCD requires systemic therapy and has a relapse risk. Poor prognostic markers include anemia, hypoalbuminemia, and organomegaly. Collaborative research is critical to unravel CD’s complexity and improve outcomes.

Fields of Study & Subjects

Viral-associated cancers and disorders Lymphadenopathy Diagnosis and Analysis IgG4-Related and Inflammatory Diseases

Publication details

Journal / source
IntechOpen eBooks
Publication date
25 March 2026
Language
EN
Document type
Book chapter